IL17A and neoplasm: In light of recent advances in the protocol for DOT cell generation26–28, our modified expansion protocol eliminates the need for αβ T depletion and enriches Vδ1+ T cells with antitumor immunity instead of the protumor IL-17-producing γδ T subsets that have been shown to promote tumor progression60,61.